[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Royal North Shore Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":243},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,47,67,87,109,127,156,183,212],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100549320","3d-printed-custom-applicators-for-hdr-bt-disco-100549320",false,"NCT06432478","3D Printed Custom Applicators for HDR BT (DISCO)","Study of 3D-printed Custom Applicators for Intracavitary HDR Gynaecological Brachytherapy (DISCO)","Inclusion Criteria:\n\n* Able to give informed consent\n* Patients indicated for intracavitary brachytherapy\n* FIGO stage I-IVA\n* ECOG 0-2\n* Primary endometrial cancer, primary vaginal cancer, primary vulva cancer, recurrent gynaecological cancer\n\nExclusion Criteria:\n\n* Pregnancy\n* Patients contraindicated for brachytherapy\n* Inflammatory bowel disease\u002Fhistory of adhesions\u002Fbowel obstruction\n* Renal transplant\u002Fhorseshoe kidney\n* Patients with significant LVSI or pelvic sidewall invasion\n* Patients requiring interstitial brachytherapy implants","FEMALE","18 Years",{"count":19,"type":20},10,"ESTIMATED","INTERVENTIONAL",[23],"NA","Intracavitary brachytherapy for gynaecological cancer currently use cylinder-type applicators or custom wax moulds to place a radioactive source in close proximity to the treatment area and provide highly conformal dose distributions. This study is a Phase IIa non-randomised interventional pilot trial that will investigate the feasibility of successfully treating patients with 3D-printed custom applicators.",[26,27,28,29],"Gynecologic Cancer","Endometrial Cancer","Vaginal Cancer","Vulva Cancer",[31,32,33],"3D-printed applicator","Gynaecological Cancer","Brachytherapy","RECRUITING","2026-02-04",{"date":37,"type":38},"2026-02-06","ACTUAL",{"date":40,"type":38},"2023-11-24",{"date":42,"type":20},"2028-09",{"name":44,"class":45},"Royal North Shore Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":4,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":46},"100412328","advanced-techniques-for-single-fraction-palliative-radiotherapy-versus-standard-multi-fraction-radiation-100412328","NCT04649125","Advanced Techniques For Single-fraction Palliative Radiotherapy Versus Standard Multi Fraction Radiation","ASPIRE_Multi","Inclusion Criteria:\n\n* Metastatic cancer\n* Recommended for 5-10 fractions palliative radiation\n* Patients with spinal cord compression are eligible for enrolment\n\nExclusion Criteria:\n\n* Unwilling or unable to give informed consent\n* Patients who are recommended for single fraction palliative radiation","ALL",{"count":56,"type":20},100,[23],"The aim of the study is to determine if single fraction dose escalated palliative radiotherapy results in a prolonged duration of benefit for patients otherwise suitable for Multifraction (5-10#) palliative radiation. The primary endpointis to determine the percentage of patients who have achieved a substantial benefit from palliative radiotherapy and have not redeveloped symptoms by 12 months post treatment",[60],"Palliative Radiotherapy",{"date":37,"type":38},{"date":63,"type":38},"2021-05-31",{"date":65,"type":20},"2026-06-30",{"name":44,"class":45},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":74,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":81,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":46},"100291400","focal-radiotherapy-for-previously-treated-prostate-cancer-patients-100291400","NCT03073278","Focal Radiotherapy for Previously Treated Prostate Cancer Patients","Phase I Feasibility Trial of Stereotactic Re-irradiation of Prostate Cancer Recurrence Within the Definitively Irradiated Prostate","Inclusion Criteria:\n\n* Men \\> 4yrs from external beam radiotherapy (EBRT) meeting the Phoenix definition of biochemical failure or men \\> 5yrs from EBRT if neo-adjuvant and\u002For adjuvant androgen deprivation therapy (ADT) also used\n* Recurrence localised to less than 1 lobe of prostate on both PMSA and multi-parametric MRI (less than equal to cT2a)\n* Recurrence must be biopsy proven, with positive biopsies limited to the PET and MRI suspicious region.\n* Life expectancy at least 10yrs from time of SBRT\n* PSA \\\u003C 10\n\nExclusion Criteria:\n\n* Recurrence in immediate proximity to rectum (unless able to have hydrogel)\n* Grade 3 or more toxicity from previous EBRT\n* Contra-indicated for fiducial insertion\n* GS 8,9 or 10 disease previously (relative - consider if decent disease free interval)","MALE",{"count":76,"type":20},36,[23],"To examine the feasibility, safety and toxicity of focal stereotactic radiation treatment (SBRT) for locally recurrent prostate cancer.",[80],"Locally Recurrent Prostate Cancer",{"date":37,"type":38},{"date":83,"type":38},"2017-04-24",{"date":85,"type":20},"2027-03-31",{"name":44,"class":45},{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":54,"minAge":17,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":21,"phases":97,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":46},"100566042","pelvis-adaptive-radiotherapy-art-100566042","NCT06650033","Pelvis Adaptive Radiotherapy (ART)","Pelvis Adaptive Radiation Therapy","Pelvis ART","Inclusion Criteria:\n\n1. Age \\> 18\n2. ECOG performance status 0-2\n3. Patients receiving curative or adjuvant pelvic radiation including:\n\n   1. Prostate cancer where nodal treatment is required\n   2. Prostate cancer post prostatectomy\n   3. Bladder cancer\n   4. Rectal cancer\n   5. Anal cancer\n   6. Adjuvant radiotherapy for gynaecological cancers\n   7. Pelvic Lymph nodes only\n4. Ability to understand and the willingness to sign an informed consent\n\nExclusion Criteria:\n\n* Hip prosthesis\n* Patient separation from approximate radiation centre to skin edge \\> 24cm, measured on diagnostic scan",{"count":96,"type":20},280,[23],"Pelvis Adaptive radiotherapy (ART) is a two phase study looking at using adaptive radiotherapy to help reduce toxicity for cancer patients having radiotherapy in the pelvic region.\n\nAdaptive radiotherapy is a new technology that provides the ability to account for daily changes in anatomy. Adaptive radiotherapy also provides a foundation for which radiotherapy margins might be safely reduced.\n\nPhase 1 of this study is looking to see if a radiation therapist centred adaptive workflow can be implemented. If phase 1 of this study is safe and feasible, the study will proceed to phase 2. Phase 2 of the study looks at using adaptive technology to reduce radiation treatment margins. The primary aim of this study is to see whether margin reduced treatment using adaptive radiotherapy can reduce side effects for patients with cancer in the pelvic area.",[100],"Pelvis Neoplasms","2026-02-03",{"date":103,"type":38},"2026-02-05",{"date":105,"type":38},"2025-10-09",{"date":107,"type":20},"2031-11-30",{"name":44,"class":45},{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":74,"minAge":17,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":21,"phases":117,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":121,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":46},"100558152","prostate-adaptive-radiation-therapy-100558152","NCT06547398","Prostate Adaptive Radiation Therapy","Inclusion Criteria:\n\n1. \\- Age \\> 18\n2. Biopsy proven prostate malignancy\n3. Definitive treatment is radiotherapy to the prostate alone\n4. ECOG performance status 0-2\n5. Ability to understand and the willingness to sign an informed consent\n\nExclusion Criteria:\n\n1. Hip prosthesis\n2. Patient separation from prostate centre to skin edge \\> 24cm, measured on diagnostic scan-",{"count":116,"type":20},130,[23],"Prostate ART is a two phase study looking at using adaptive radiotherapy to help reduce toxicity for prostate cancer patients.\n\nAdaptive radiotherapy is a new technology that provides the ability to account for daily changes in anatomy. Adaptive radiotherapy also provides a foundation for which radiotherapy margins might be safely reduced.\n\nPhase 1 of this study is looking to see if a radiation therapist centred adaptive workflow can be implemented. If phase 1 of this study is safe and feasible, the study will proceed to phase 2.\n\nPart 2 of the study looks at using adaptive technology to reduce radiation treatment margins. The primary aim of this study is to see whether margin reduced treatment using adaptive radiotherapy can reduce side effects for prostate cancer patients.",[120],"Prostatic Neoplasms",{"date":103,"type":38},{"date":123,"type":38},"2025-10-01",{"date":125,"type":20},"2031-10-31",{"name":44,"class":45},{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":135,"sex":54,"minAge":17,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":21,"phases":138,"briefSummary":139,"conditions":140,"keywords":146,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":155},"100558090","locally-optimised-contouring-with-ai-technology-for-radiotherapy-100558090","NCT06546592","Locally Optimised Contouring With AI Technology for Radiotherapy","LOCATOR - Locally Optimised Contouring With AI Technology for Radiotherapy","LOCATOR","Inclusion Criteria:\n\n* 18 years and older who are planned for primary breast malignancy\n* ECOG performance 0-2\n* Ability to understand and willingness to sign a written informed consent document\n* The target volume must be able to be objectively reviewed by current published national or international clinical guidelines\n\nExclusion Criteria:\n\n* Patients under 18 years of age\n* Patients unable to understand consent documents",true,{"count":137,"type":20},444,[23],"LOCATOR is a multicentre phase II randomised clinical trial that is looking at the process of contouring in radiation treatment for breast cancer patients. This study looks at whether contouring aided by artificial intelligence (AI) is comparable in quality to that of contouring done completely manually by a radiation oncologist. We are also looking at whether AI assisted contouring saves radiation oncologists time when compared to fully manual contouring.\n\nLOCATOR uses the LOCATOR software which is an in-house software developed locally and trained on local data.",[141,142,143,144,145],"Contouring","Segmentation","Radiation Therapy","Artificial Intelligence","Deep Learning",[141,142,143,144,145],"2026-01-27",{"date":149,"type":38},"2026-01-29",{"date":151,"type":38},"2025-02-11",{"date":153,"type":20},"2030-04-30",{"name":44,"class":45},3,{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":54,"minAge":17,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":21,"phases":166,"briefSummary":167,"conditions":168,"keywords":170,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":46},"100539682","de-escalation-of-radiation-dose-in-hpv-associated-opc-utilising-fmiso-pet-de-radiate-100539682","NCT06307015","De-escalation of Radiation Dose in HPV-associated OPC Utilising FMISO PET (DE-RADIATE)","De-escalation of Radiation Dose in HPV-associated Oropharyngeal Squamous Cell Carcinoma Utilising FMISO PET and Magnetic Resonance Imaging as Non-Invasive Biomarkers of Hypoxia (DE-RADIATE)","DE-RADIATE","Inclusion Criteria:\n\n* Age \\> 18 years\n* Histologically confirmed cT1-2N1-2b oropharyngeal squamous cell carcinoma or cTxN1-2 carcinoma of unknown primary\n* p16 positive (70% nuclear and cytoplasmic staining) and HPV positive (genotyping via PCR) tumours of the tonsil, base of tongue, glossotonsillar sulcus, or unknown primary site (suspected mucosal origin).\n* No contraindications to radiotherapy, platinum-based chemotherapy or surgery\n* No contraindications to PET\u002FCT or MRI\n* Eastern Cooperative Oncology Group (ECOG) performance status score 0-2 (KPS \\> 70%)\n* Ability to understand and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Women lactating, pregnant or of childbearing potential who are not willing to avoid pregnancy during the study\n* Patients with a history of severe renal disease(s) (eGFR \\\u003C20) than cannot tolerate gadolinium chelate contrast agents.)\n* ECOG ≥ 3\n* Previous high dose radiation therapy to the head or neck\n* Patients unwilling or unable to have PET\u002FCT or MRI\n* Geographically remote patients unable to agree to imaging schedule\n* Patients with a history of psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study.\n* Patients with significant cardiac or pulmonary disease including cardiac arrythmias or Chronic Obstructive Pulmonary Disease (COPD) that are unable to tolerate high flow O2 for oxygen contrast.\n* Patients taking carbonic anhydrase inhibitors (acetazolamide)\n* History of glaucoma\n* Any implant, foreign body, 3T MRI incompatible device, or other contraindication to MRI imaging",{"count":165,"type":20},25,[23],"The goal of this prospective clinical trial is to determine if HPV-associated oropharyngeal squamous cell carcinoma that is non-hypoxic on FMISO PET can be successfully treated with a lower dose of radiation therapy.\n\nThe main questions it aims to answer are:\n\n1. What is the pathologic complete response rate in patients selected for radiation dose de-escalation and neck dissection?\n2. What is the correlation between MRI and FMISO PET assessment of hypoxia before and during RT?\n3. What are the acute and late toxicities in patients selected for radiation dose de-escalation?\n4. What are the quality of life scores in patients selected for radiation dose de-escalation?\n5. What are the local, regional and distant failure rates of patients selected for radiation dose de-escalation?\n\nPatients with cT1-2N1-2b (AJCC 7th edition) oropharyngeal tumours will undergo surgical resection of the primary tumour. Following this, they will be allocated to standard radiation therapy (70Gy with concurrent cisplatin chemotherapy) or de-escalation radiation therapy (30Gy with concurrent cisplatin chemotherapy) based on the results of FMISO PET. Patients with non-hypoxic tumours at baseline OR after two weeks of radiation therapy will be allocated to the de-escalated group. 3-4 months after completion of radiation therapy, all patients in the de-escalated group will undergo mandatory neck dissection to assess pathologic response.\n\nResearchers will assess the pathologic response rate after surgery in the de-escalation group. They will also compare the outcomes (oncological outcomes and quality of life) between the group receiving the standard treatment (70Gy) and the group receiving de-escalated radiation therapy (30Gy).",[169],"HPV Positive Oropharyngeal Squamous Cell Carcinoma",[171,172,173,174],"Radiation therapy","De-escalation","FMISO PET","Hypoxia","2025-07-25",{"date":177,"type":38},"2025-07-30",{"date":179,"type":38},"2025-04-01",{"date":181,"type":20},"2031-12",{"name":44,"class":45},{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":54,"minAge":17,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":21,"phases":194,"briefSummary":196,"conditions":197,"keywords":200,"overallStatus":203,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":4},"100529964","phase-2-tirzepatide-for-the-treatment-of-concurrent-type-1-diabetes-and-overweight-or-obesity-100529964","NCT06180616","Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity","Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity: A Placebo-Matched Randomised Controlled Trial","TZP-T1D","Inclusion Criteria:\n\n* Age 18-70 years at screening\n* A clinical diagnosis of T1D for at least 12 months at time of screening\n* Body mass index ≥ 27kg\u002Fm2\n* HbA1c ≤ 10%\n* Capable and willing to self-inject tirzepatide once per week\n* In women of childbearing potential, a negative pregnancy test and willing to use effective contraception consistently for the duration of the study\n* Able and willing to provide written informed consent for study participation\n* Able and willing to use Easy Diet Diary\n* Able and willing to keep an exercise log\n* Willing to share devices data uploads\n* Has current glucagon product to treat severe hypoglycaemia\n* Has current ketone meters to check ketones\n\nExclusion Criteria:\n\n* Age \\\u003C18 years and \\>70 years\n* A clinical diagnosis of diabetes type other than T1D\n* HbA1c \\> 10%\n* Use of GLP-1 receptor agonist within 1 month of study screening\n* Use of any glucose lowering medications aside from insulin within 1 month of study screening\n* History of hypersensitivity to investigational medicinal product or related product\n* Obesity that is induced by other endocrine disorders\n* Pregnancy or positive pregnancy test at time of screening, or unwilling to use effective contraception consistently for the duration of the study which is defined in Appendix 1\n* Active proliferative diabetic retinopathy, maculopathy, or severe no proliferative diabetic retinopathy requiring acute treatment\n* Known gastric emptying abnormality\n* History of chronic or acute pancreatitis, uncontrolled hypertension, acute cardiovascular condition within 3 months\n* No longer than 12 months of insulin treatment\n* Not willing to use a NovoPen 6 to record insulin dosing if currently using multiple daily injections\n* Insulin pump, CGM or smart phone devices are not compatible for data transfer\n* Not willing to share device data\n* Current use of any steroidal medication, or planned long-term steroidal treatment (\\>4 weeks) during the study period\n* Serum triglycerides \\>500 mg\u002FdL\n* History of or plans for bariatric surgery during the study period\n* eGFR \\\u003C45 ml\u002Fmin\u002F1.73 m2\n* History of severe hypoglycaemia (within 3 months of trial period)\n* History of diabetic ketoacidosis (within 3 months of trial period)\n* History of stroke (within 3 months of trial period)\n* History of heart failure\n* Planned coronary, carotid, or peripheral artery revascularisation\n* History of acute or chronic liver disease\n* History of allergy to any form of insulin, GLP-1RA or its excipients\n* History of malignancy requiring chemotherapy, surgery, or radiation (within 5 years of trial period)\n* History of multiple endocrine neoplasia type 2, familial thyroid cancer, or non-familial medullary thyroid cancer\n* Presence or history of malignant neoplasms or in situ carcinomas (other than basal or squamous cell skin cancer, low-risk prostate cancer, or in situ carcinomas of the cervix or carcinoma in situ\u002Fhigh grade prostatic intraepithelial neoplasia) within 5 years before screening\n* Have a pacemaker, or metal implants\n* Participation in other intervention trials during the study period\n* Existence of any additional health conditions or medical issues, including significant psychiatric disorders, that render a person unfit for the study at the discretion of the investigators","70 Years",{"count":193,"type":20},40,[195],"PHASE2","This study is a 2-arm, double blinded, randomised clinical trial where 40 participants will be assigned 1:1 to insulin treatment alone (control) or insulin treatment and tirzepatide treatment for 32 weeks. The primary objective is to demonstrate that tirzepatide treatment, dose incremented to 15mg QW for 32 weeks adjunctive to insulin treatment can reduce body weight in patients with T1D and overweight or obesity when compared to insulin treatment alone. The secondary objective is to demonstrate that tirzepatide treatment, dose incremented to 15mg QW for 32 weeks can improve glycaemic control (measured by hbA1c), improve time in range, reduce insulin requirements, and reduce the severity of comorbidities in people with obesity and T1D. This trial includes a 6 month follow-up period.",[198,199],"Type 1 Diabetes Mellitus","Overweight and Obesity",[201,202],"Tirzepatide","GLP-1\u002FGIP Agonist","NOT_YET_RECRUITING","2025-07-24",{"date":206,"type":38},"2025-07-29",{"date":208,"type":20},"2026-12",{"date":210,"type":20},"2028-12",{"name":44,"class":45},{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":54,"minAge":17,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":222,"phases":4,"briefSummary":223,"conditions":224,"keywords":227,"overallStatus":203,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":46},"100597007","the-effect-of-glioblastoma-psma-expression-following-tumour-vegf-blockade-from-bevacizumab-100597007","NCT07052877","The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab","Investigating Glioblastoma PSMA Expression by Utilizing Anti-VEGF and Its Effect on PSMA PET Scan Avidity","GUAVA","Inclusion Criteria:\n\n* \\> 18 year of age\n* ECOG 0-2\n* Able to provide informed consent for the study\n* Minimum of 1 month from completion of radiotherapy with clinical or radiography evidence suggesting residual tumour\n* Confirmed glioblastoma IDH1\u002F2 wildtype (WHO2021)\n* For bevacizumab treatment as per treating physician\n* Able to comply with trial requirements\n\nExclusion Criteria:\n\n* No major organ impairment that would likely lead to unacceptable toxicities- eg significant cardiac, hepatic, renal or haematologic dysfunction (based on clinician assessment)\n* Any contraindication to bevacizumab, MRI gadolinium contrast or 68Ga-PSMA-617 radioisotope\n* Any implant, foreign body, 3T MRI incompatible device or other contraindication to MRI imaging\n* Does not fulfill PBS requirements for bevacizumab\n* Women lactating, pregnant or of child baring potential who are not willing to avoid pregnancy during the study",{"count":221,"type":20},20,"OBSERVATIONAL","This trial is a single arm study for patients receiving bevacizumab for IDH-wildtype glioblastoma. Patients receiving bevacizumab (an anti-VEGF therapy) will receive PSMA scans to investigate the role of PSMA expression in glioblastoma and its relationship to VEGF expression.",[225,226],"Glioblastoma","Glioblastoma Multiforme (GBM)",[228,229,230,231,232,233,234],"glioblastoma","anti-VEGF","PSMA","bevacizumab","VEGF","glioma","astrocytoma","2025-07-08",{"date":237,"type":38},"2025-07-11",{"date":239,"type":20},"2025-07",{"date":241,"type":20},"2027-07",{"name":44,"class":45},""]